Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Roche’s Genentech unit will spend $725 million to buy Seragon Pharmaceuticals, a privately held biotech firm in San Diego. Founded in 2013, Seragon is developing selective estrogen receptor degraders (SERDs) for treating hormone receptor-positive cancers. Genentech will get Seragon’s collection of small-molecule SERDs, including one targeting breast cancer that is in Phase I development. Genentech could pay up to $1 billion more should Seragon’s candidates hit certain milestones.
This article has been sent to the following recipient: